Specifically, the upregulation of CD25+ T cells plays a cardinal role in this therapeutic landscape, opening new horizons for innovative and effective treatment modalities for patients grappling with post-MI cardiac dysfunction. The gene discussed is IL2RA; the disease is myocardial infarction.